samedan logo
 
 
spacer
home > pmps > winter 2002 > clinical trial supplies - the essential link
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Clinical Trial Supplies - The Essential Link

Strategically positioned within the bio/pharma development pipeline, at the very centre of the clinical trials process, resides a 'hardware' component: the test article or clinical trial material (CTM).

The outcome of field tests for this essential link in the chain is crucial to future success of investment in R&D. Given the strategic importance of procuring CTM, it's not surprising that the complex clinical trial supplies (CTS) business absorbs a hefty chunk of a sponsor's development budget. Trials can no longer be set up in-house using homemade trial packs, labelled by hand and randomly assigned to patients with little or no control. Today's CTS business is a slick, highly sophisticated operation which is considered a microcosm of the wider pharmaceutical industry. This article will review aspects of the modern CTS business.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Patricia Lobo, Editor of PMPS and Senior Consultant in CTS and Manufacturing at Technomark Consulting Services Ltd
spacer
Dr Patricia Lobo
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera launches UniSpray, its unidose system primarily for systemic-acting drug administration

Nemera has a proven track record in developing and manufacturing complex Ear Nose and Throat solutions. In line with clear growing market interest in unidose system coupled with promising advantages that nasal route could offer, Nemera is thrilled to extend its portfolio by launching its unidose system, UniSpray, for systemic-acting drug administration to face emergency and crisis.
More info >>

White Papers

Key to Outsourcing Method Development and Validation: A Pragmatic Approach

RSSL

In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developerís mind set and a regulatory background in validation. As companies are focussing on achieving ever shorter times of drug to market, it is vital that a tailored, pragmatic approach is adopted when engaging in both method development and validation activities for an Active Pharmaceutical Ingredient (API) or drug product (DP). Although methods still require a high degree of robustness, the overall strategy should encompass a full evaluation of the regulatory requirements applicable to the particular phase of the drug life-cycle; this is pivotal in Key to Outsourcing Method Development and Validation A Pragmatic Approach order to ensure a successful regulatory submission, where the applicant must demonstrate suitable validation of all methods used to support the filing.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement